Shares of Corcept Therapeutics Inc. (CORT) are up over 85% at $101.48 today, following encouraging data from its phase III trial of Relacorilant in patients with platinum-resistant ovarian cancer, dubbed ROSELLA.
In the ROSELLA trial, the enrolled 381 patients with platinum-resistant ovarian cancer, were randomized 1:1 to receive either Relacorilant plus nab-paclitaxel or nab-paclitaxel alone.
According to the trial findings:
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.